BioScrip Mulls Asset Sales to WAG - Analyst Blog
03 Février 2012 - 6:17PM
Zacks
Specialty pharmacy services provider, BioScrip
Inc. (BIOS) recently announced its decision to dispense
with certain community specialty pharmacies and mail service
pharmacy business assets to leading drugstore retailer
Walgreen Corp. (WAG) for $225 million.
Walgreen's will initially pay $170 million in cash at the
closing of the deal, expected in late April 2012. BioScrip will
also retain certain accounts receivable and working capital
liabilities of $55 million based on its balance sheet at December
31, 2011.
Moreover, BioScrip may also gain an additional $60 million from
Walgreen's depending on whether Walgreen's retains certain business
included in the transferred businesses. Revenues from the
transferred business for the nine-months ending September 30, 2011
were $938.5 million with gross profit of $73.7 million (7.9% of
sales).
While BioScrip expects this transaction to be accretive to its
earnings in 2012, Walgreen's anticipates the transaction to have no
material impact on its earnings in fiscal 2012. However, the
transaction will be moderately accretive in fiscal 2013.
Following the announcement of the deal, BioScrip's shares shot
up 15.07% to $6.72 on Thursday while Walgreen's stock rose 1% to
$33.53.
Walgreen's believes that the acquisition is a strategic fit and
will strengthen its pharmacy services business. With this
transaction, Walgreen's will get hold of BioScrip’s community
specialty pharmacy business in 30 locations across 16 states in the
US and the District of Columbia, primarily serving HIV, oncology
and transplant patients.
In addition to that, Walgreen's will also gain some assets of
BioScrip's centralized specialty pharmacy business and traditional
mail service pharmacy business that dispenses prescriptions for
drugstore.com (acquired by Walgreen's in June 2011).
On the financial front, as per the last reported quarter,
BioScrip had a highly leveraged balance sheet. Despite lowering its
debt by $27.5 million during the quarter, BioScrip had $278.9
million in total long-term debt, much higher than $206.4 million in
stockholders’ equity.
BioScrip believes that this transaction will also help the
company emphasize more on areas with long-term growth potentials
and high returns. The company plans to deploy corporate resources
more on Infusion/Home Health industry where it has meaningful
strengths and competitive advantages.
With favorable demographic trends, including an aging population
in the US, the company is very much optimistic about the future
growth prospect of the home health industry. According to the
estimates of the National Home Infusion Association (NHIA),
alternate-site infusion therapy sector currently represents $9–$11
billion per year in US health care expenditures.
BioScrip presently retains a short-term Zacks #1 Rank (Strong
Buy). Walgreen's, on other hand, maintains a short-term Zacks #3
Rank (Hold).
BIOSCRIP INC (BIOS): Free Stock Analysis Report
WALGREEN CO (WAG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024